LYMPHOGRANULOMA VENEREUM (LGV) is a sexually transmitted infection (STI) that was originally confined to equatorial areas.1 In 2004, a cluster of LGV cases was reported in Rotterdam [2 to 4]. All were men who had sex with men (MSM) and most were human immunodeficiency virus (HIV) seropositive. Other industrialized countries in Europe, North America, and Australia also reported LGV cases in MSM recently.3,5
LGV is caused by Chlamydia trachomatis (CT) L serovars (comprising L1, L2, L2′, and L3). They elicit an invasive infection affecting submucosal connective tissue layers and lymphatic dissemination to locoregional lymph nodes.6 In contrast, CT serovars D-K are responsible for urogenital and anorectal chlamydia infections confined to the mucosal layer, with mild to asymptomatic clinical presentations.
All LGV cases in Amsterdam are caused by a unique chlamydia strain identified as L2b,7 and have been detected retrospectively in anal swabs from STI clinic visitors in Amsterdam as early as 2000 (no samples from an earlier date were available). Surprisingly, the same L2b strain was detected in anal swabs collected at a San Francisco STI clinic back in at least 1981.7,8 These findings suggest a re-emerging infection that had gone unnoticed for at least 20 years, rather than a new outbreak of LGV. Although routine STI screening included CT testing in this period, the standard procedure did not comprise LGV diagnostics (serovar typing or CT serology).
We previously showed in a retrospective study that HIV status, anoscopy, and the abundant presence of white blood cells in Gram stained anorectal smears help to predict LGV infections, and can support the clinical decision to start syndromic treatment in MSM reporting receptive anal intercourse before definite polymerase chain reaction (PCR) results are available.9 Here we describe results of a cross-sectional study started shortly after the recent outbreak of LGV in 2004. We investigated the relationships between potential risk factors and LGV among MSM.
Study Setting and Participants
The STI outpatient clinic of the Health Service Amsterdam is the largest inner city institute for diagnosing and treating STI in the Netherlands. It offers screening and free-of-charge treatment to approximately 24,000 clients a year, many of whom are self-referred.10 All MSM visitors reporting receptive anal intercourse in the previous 6 months undergo anoscopy on routine basis, and for all, anorectal swabs for Gram-staining, CT, and gonorrhea testing are obtained. If an anorectal swab is positive for CT, our real-time PCR to exclude LGV is performed.11 We exclude syphilis, genital herpes, and LGV in case of inguinal bubo's, genital, or peri-anal ulceration with dark-field microscopy, syphilis serology, and specific PCR tests for Treponema pallidum, herpes simplex viruses 1 and 2 and CT.
This study was approved by the Ethical Committee of the Academic Medical Center, Amsterdam, The Netherlands. In the period August 2004 to August 2006, from consenting MSM reporting receptive anal contact within the previous 6 months, we included those with at least 1 of the 4 most prevalent proctitis diagnoses among MSM in our clinic. These are respectively, proctitis of unknown etiology, non-LGV chlamydial proctitis, gonorrheal proctitis, and LGV proctitis (LGVP).12 MSM with less prevalent diagnoses like herpetic and syphilitic proctitis were not included in the study. A non-LGV chlamydial proctitis, gonorrheal proctitis, or LGVP diagnosis was based on definite cultivation and/or PCR results in anorectal swabs. A diagnosis of a proctitis of unknown etiology was based on the following criteria: (a) signs of hypervascularity, edema, discharge, ulcerations, fistulas, abscesses upon anoscopy, and/or more than 10 white blood cells per high power field in a Gram stained anorectal smear upon first visit, and (b) exclusion of STI organisms (i.e., Neisseria gonorrhoeae by cultivation and CT, Treponema pallidum, herpes simplex 1 and 2 by PCR) after 1 week.
As part of the standard STI screening, client characteristics (e.g., complaints, sexual behavior, and previous STI diagnoses), physical findings, laboratory results, current diagnoses, and therapy were recorded in an electronic patient database. Besides the STI diagnostics collected as part of the standard procedure and described earlier,9 participants were tested as part of the current study for CT serology (Chlamydia trachomatis-IgG-pELISA, medac Diagnostika, Germany), hepatitis B serology (antibody to hepatitis B virus core antigen recombinant, Axsym system, Abbott, Germany), and hepatitis C serology (HCV version 3.0, Axsym System, Abbott, Germany, confirmed with Deciscan HCV plus, Bio-rad, Hercules, CA). For HIV-seropositive participants, on their consent, we obtained the CD4 count, CD8 count, and viral load measurement taken most closely both before and after the date of study inclusion, and the start date of antiretroviral therapy (ART) from the national HIV Monitoring Foundation. Also, at study inclusion, a public health nurse interviewed participants about sexual risk behavior within the previous 6 months, according to a specifically designed questionnaire. Information was collected on traceable partners (partners who can be contacted by telephone, e-mail and/or home address) and anonymous partners (nontraceable partners).
In case of anal coinfections leading to more than 1 proctitis diagnosis, men were allocated to a proctitis group according to the following hierarchy, which was based on the diagnostic frequency among our MSM clinic attendees during 1 year: LGVP, gonorrheal proctitis, non-LGV chlamydial proctitis, and proctitis of unknown etiology. This was done because we expected the most network-associated factors in the least prevalent proctitis group. Therefore, men with an LGVP (least prevalent among MSM clinic attendees) and gonorrheal proctitis were included in the LGVP group, whereas men with gonorrheal proctitis and non-LGV chlamydial proctitis (being more prevalent than gonorrheal proctitis among MSM clinic attendees) were included in the gonorrheal proctitis group.
Differences in background characteristics, clinical signs, markers of HIV disease progression if diagnosed HIV-positive, and sexual risk behaviors across men with LGVP, gonorrheal proctitis, nonchlamydial proctitis or proctitis of unknown etiology were tested univariately using ANOVA or Kruskal-Wallis test (continuous variables) or Pearson χ2 test for independence, with Fisher exact test in case of small numbers (noncontinuous variables).
To assess sexual risk behaviors associated with LGV among MSM with proctitis, we first performed univariate and multivariate logistic regression analysis using STATA version 9. MSM with LGVP were compared with MSM with a non-LGVP. Variables related to sexual partners (number, type, and HIV status) and practices such as unprotected receptive anal intercourse, fisting, use of toys, use of anal enemas, anal use of elicit drugs, and location of sexual contact (dark room, park, party, home, abroad) were first evaluated univariately. Subsequently, all variables were entered in a multivariate logistic regression model. Backward selection was performed using the likelihood ratio test. To assess the robustness of our model, we also performed similar analyses restricted to MSM with signs of a proctitis based on anoscopy or more than 10 white blood cells in the anal Gram stain, irrespective of a causative STI organism. Secondly, variables included in the multivariate model were tested using multinomial logistic regression containing the 4 proctitis groups separately and using the proctitis of unknown etiology group as the reference group. A P value <0.05 was considered statistically significant.
We included 125 participants between August 2004 and August 2005 with oversampling of LGV cases for whom the inclusion period was extended until April 2006; 32 (26%) had LGVP (7 were coinfected with anal gonorrhea), 22 (18%) had gonorrheal proctitis (6 were coinfected with anal non-LGV chlamydia), 30 (24%) had non-LGV chlamydial proctitis, and 41 (48%) had proctitis of unknown etiology. We excluded 5 men with an anal swab positive for chlamydia due to inconclusive serovar determination by PCR; and we excluded 1 participant with syphilitic proctitis and 7 with herpetic proctitis.
Background and Clinical Characteristics
Overall, participants with LGVP and proctitis of unknown etiology were older than men with gonorrheal or non-LGV chlamydial proctitis (Table 1). The majority of the men with LGVP were HIV positive (78%), compared to 54% of the men with proctitis of unknown etiology, 50% of the men with gonorrheal proctitis, and 27% of the men with non-LGV chlamydial proctitis. Men with LGVP or proctitis of unknown etiology were more often positive for hepatitis B virus core antibody (65% and 59%, respectively) than men with non-LGV chlamydial (30%) or gonorrheal proctitis (23%). Both previous and concurrent syphilis and hepatitis C virus infections—although the latter 2 effects were not statistically significant—were found more often in men with LGVP than in men with proctitis of unknown etiology, gonorrheal proctitis, or non-LGV chlamydial proctitis.
The majority of the men with LGVP, gonorrheal proctitis, or proctitis of unknown etiology reported STI-related symptoms as reason for visiting the clinic compared to the minority of the men with non-LGV chlamydial proctitis. Anal discharge was reported by 44% of the men with LGVP and 32% of the men with gonorrheal proctitis, whereas only 1 person with non-LGV chlamydial proctitis reported anal discharge. Remarkably, a substantial number of men with LGVP showed no anoscopic abnormalities (40%) and reported no anal discharge (56%).
MSM with LGVP and gonorrheal proctitis had higher numbers of white blood cells in the anal Gram stain compared to men with proctitis of unknown etiology or non-LGV chlamydial proctitis. The majority (60%) of the MSM with LGVP and 20% of the MSM with proctitis of unknown etiology had a CT IgG titer of 800 or higher.
Of the 66 men with HIV-positive serology, 38 men (18 with LGVP, 6 with gonorrheal, 4 with chlamydial, and 10 with proctitis of unknown etiology) consented to retrieval of HIV data from the HIV Monitoring Foundation. The men with LGVP did not differ from MSM without LGVP in ART duration or (changes in) CD4 count, CD8 count, and HIV viral load as measured around the time of inclusion (data not shown).
Sexual Risk Factors Associated With LGVP
Of our 125 participants, 101 (81%) consented to fill in the questionnaire on sexual partners and sexual risk behavior (all 32 men with LGVP and 69/93 men, i.e., 74%, without LGVP). Men who declined did not differ significantly from the others on age, ethnicity, HIV status, or previous STI diagnosed.
First, we compared MSM with LGVP to those without LGVP using logistic regression analysis (Table 2). Unprotected receptive anal intercourse, use of enemas, anal drug use, sex in darkrooms, having sex at sex parties, and having sex with HIV-positive partners were associated with LVGP in univariate analysis. In multivariate logistic regression, LGVP remained significantly associated with use of enemas [odds ratio (OR) 7.8, 95% confidence interval (CI) 2.6 to 23.2], having sex at sex parties (OR: 5.7, 95% CI: 1.5–21.8), and having sex with HIV-positive partners (OR 3.2, 95% CI: 1.1–9.3). Surprisingly, using toys was associated with a lower LGVP risk (OR: 0.2, 95% CI: 0.04–0.6). To asses the robustness of our model we repeated our analysis restricted to MSM with proctitis based on anoscopic abnormalities or more than 10 white blood cells in the anal Gram stain, irrespective of an STI causing organism. This analysis revealed a multivariate model containing the same 4 variables as described above. The effects were comparable except that the odds ratio for the use of enemas increased to 12.0 (95% CI: 3.1–46.9).
We then compared the 4 proctitis groups separately (Table 3). A large part of the MSM with LGVP, gonorrheal proctitis, or proctitis of unknown etiology reported sexual contact with anonymous partners, whereas most of the men with non-LGV chlamydial proctitis reported sexual contact only with traceable partners. For the men reporting anonymous partners, the total number of anonymous partners did not differ significantly among the four groups but seemed lower among MSM with non-LGV chlamydial proctitis (Table 3, P = 0.22) Moreover, MSM with non-LGV chlamydial proctitis had significantly less sex in darkrooms (28%), and more often had sex with known HIV-negative partners (59%) than MSM with LGVP, gonorrheal proctitis, or proctitis of unknown etiology. Most of the MSM with LGVP reported anal enema use (69%), which was significantly more often than in MSM with gonorrheal proctitis or proctitis of unknown etiology (25% and 13%, respectively). Also 41% of the MSM with non-LGV chlamydial proctitis reported anal enema use.
Finally, we evaluated our 4 proctitis groups separately in a multinomial logistic regression model (Table 4). Similar associations with LGV as reported above were found. When comparing with the proctitis of unknown etiology group, anal enema use was associated with a higher LGVP risk (OR: 31.1, 95% CI: 5.4–180.3), a higher non-LGV chlamydial proctitis risk (OR: 8.7, 95% CI 1.6–46.7), and with a higher gonorrheal proctitis risk (OR: 3.1, 95% CI: 0.5–20.4). Toy use was associated with a lower risk for LGVP, whereas having sex at a party was associated with a higher LGVP risk.
Since the identification of numerous outbreaks of LGV among MSM in the industrialized world, those affected are limited to a network of men with high-risk behavior for STI.14 Among men with LGVP we found multiple previous STI and high HIV prevalence, reflecting high-risk behavior in this group. Additionally, apart from having sex with HIV-positive partners and having sex at a sex party, enema use was strongly associated with LGVP in our MSM population.
High-risk behavior seems to be an important factor in LGVP transmission. In addition, MSM with proctitis of unknown etiology or gonorrheal proctitis did not seem to substantially differ in their sexual risk behavior from MSM with LGVP given their high prevalence of HIV and hepatitis B virus antibodies and high levels of a previous syphilis infection, having sex with anonymous partners, and sex in darkrooms. However, MSM with LGVP more often reported sex at a sex party. This suggests that MSM with these 3 forms of proctitis are taking part in high-risk sexual networks for STI. In contrast, MSM with non-LGV chlamydial proctitis seem to take part in networks with a lower risk for STI (Table 3).
Our study suggests that enema use is the most important factor associated with LGVP, although residual confounding factors can never be excluded, and the limited number of cases in this study possibly caused relevant factors to go unnoticed. On the other hand, the association between enema use and LGVP was consistent in the different statistical models, which support its relevance in the transmission of LGVP.
Before 2004, standard STI screening in industrialized countries did not include specific LGV diagnostics. It is nevertheless puzzling that the LGV epidemic could spread worldwide and remain unnoticed for so long. We earlier speculated9 that the increase could be explained by the immune restoration inflammatory syn-drome, which is characterized by paradoxical infectious and inflammatory processes in immune-compromised HIV patients soon after starting ART.15 HIV patients with asymptomatic LGVP would thus become symptomatic the moment their immune system responded to ART, but this was not confirmed by the current study. Most HIV-positive men with LGVP had been on ART for several years before LGVP was diagnosed. Moreover, no sudden signs of immune restoration (CD4 count increase, HIV viral load decrease) could be demonstrated around the time of LGVP diagnosis. Therefore, it seems unlikely that immune restoration inflammatory syndrome caused the sudden identification of LGV outbreaks.
Even though most men diagnosed with LGVP visited the clinic because of STI-related complaints and/or showed abnormalities upon anoscopy, 40% of the men with LGVP reported few complaints and/or had no physical abnormalities. This was in accordance with our previous findings in a retrospective case control study.9 Because these mild cases can delay the diagnosis and hamper screening and prevention measures, clinicians should not count on patient complaints and/or proctoscopic findings alone to identify LGVP. Serovar determination to exclude LGV is therefore advisable in MSM with a PCR-positive anorectal chlamydia infection.11,16 In case serovar determination is unavailable, a white blood cell count in Gram stain smears from anal mucosa, HIV-testing, and anoscopy can be useful in discriminating non-LGV chlamydial proctitis from LGVP.9
Hepatitis C antibodies were detected in 4 out of 32 men with LGVP (13%), supporting earlier reports that hepatitis C infection seems sexually transmissible among MSM, particularly in high risk MSM networks.17 Why the use of toys was negatively associated with LGVP is unclear but our findings are in contrast with the previously suggested role of toy use in the transmission of LGV.3 All 4 studied forms of proctitis (gonorrhoeal proctitis, non-LGV chlamydial proctitis, proctitis of unknown etiology, and LGVP) could be transmitted through the rectal exposure to rectal excretions during the sharing of toys and fisting. Our study eliminates the association with these sexual practices.
MSM reporting receptive anal intercourse often take anal enemas before having sex for reasons of hygiene.18 Anal enemas have been shown to be associated with sexual transmission of hepatitis B19 and hepatitis C.20 To our knowledge, we describe here for the first time their possible role as a risk factor for STI-related forms of proctitis like LGVP, and also for non-LGV chlamydial proctitis (and to a lesser extent for gonorrhoeal proctitis) given the substantial increased odds when compared to men with proctitis of unknown etiology (Table 4).
When preliminary analysis revealed that enema use was associated with LGVP, we designed and implemented an additional questionnaire focused on the practice of enema use. This questionnaire was completed by 68 (of 125) participants, of whom 22 were MSM with LGVP. Most men took anal enemas and all used tap water. One person added salt, another added soap to the water; both did not have LGVP. The majority irrigated using a hose connected to the water supply system, whereas a minority irrigated with water using a douche ball. About one-quarter shared their enema equipment with others, but this was not significantly associated with any of the study groups (data not shown).
To identify both symptomatic as well as asymptomatic LGV cases among MSM, we have developed a routine screenings method. As described in the methods section, all patients reporting receptive anal intercourse in the previous 6 months undergo anoscopy, and anorectal swabs for Gram-staining CT and gonorrhea testing are obtained. In case anal chlamydia is diagnosed, additional serovar determination is performed to exclude LGVP. Moreover, chlamydia diagnostic is performed on all genital and perianal ulceration to exclude inguinal forms of LGV. Because of this routine procedure, we were able to show that the LGV epidemic in 2007 is ongoing in the Netherlands.21
Why enema use is associated with STI transmission can be speculated upon. The additional information on enema use taught us that it is likely the irrigation procedure itself and not an aggressive substance added to the water used, because almost all men reported the use of water only when using enemas. The disruption of the mucosal barrier caused by anal irrigation before receptive anal intercourse facilitates transmission of STI pathogens, and also of bloodborne viruses such as hepatitis B virus and hepatitis C virus.19,20 Discouraging the use of enemas as such seems warranted. These findings stress the importance of further research on the biologic effects (as we plan to do) and also behavioral effects of anal enemas on the transmission of STI in general and LGVP in particular.
1. Perine PL, Stamm WE. Lymphogranuloma venereum. In: Holmes KK, Sparling PF, Mardh PA, Lemon SM, Stamm WE, Piot P, et al., eds. Sexually Transmitted Diseases. 3rd ed. New York: McGraw-Hill, 1999: 423–432.
2. Nieuwenhuis RF, Ossewaarde JM, van der Meijden WI, Neumann HA. Unusual presentation of early lymphogranuloma venereum in an HIV-1 infected patient: Effective treatment with 1 g azithromycin. Sex Transm Infect 2003; 79:453–455.
3. Nieuwenhuis RF, Ossewaarde JM, Gotz HM, et al. Resurgence of lymphogranuloma venereum in Western Europe: An outbreak of Chlamydia trachomatis
serovar l2 proctitis in The Netherlands among men who have sex with men. Clin Infect Dis 2004; 39:996–1003.
4. Lymphogranuloma venereum among men who have sex with men–Netherlands, 2003–2004. MMWR Morb Mortal Wkly Rep 2004; 53:985–988.
5. Blank S, Schillinger JA, Harbatkin D. Lymphogranuloma venereum in the industrialised world. Lancet 2005; 365:1607–1608.
6. Davis BT, Thiim M, Zukerberg LR. Case records of the Massachusetts General Hospital. Case 2–2006. A 31-year-old, HIV-positive man with rectal pain. N Engl J Med 2006 19;354:284–289.
7. Spaargaren J, Fennema HS, Morre SA, de Vries HJ, Coutinho RA. New lymphogranuloma venereum Chlamydia trachomatis
variant, Amsterdam. Emerg Infect Dis 2005; 11:1090–1092.
8. Spaargaren J, Schachter J, Moncada J, et al. Slow epidemic of lymphogranuloma venereum L2b strain. Emerg Infect Dis 2005; 11:1787–1788.
9. Van der Bij AK, Spaargaren J, Morre SA, et al. Diagnostic and clinical implications of anorectal lymphogranuloma venereum in men who have sex with men: A retrospective case-control study. Clin Infect Dis 2006 15;42:186–194.
10. Heijman TL, Van der Bij AK, de Vries HJ, van Leent EJ, Thiesbrummel HF, Fennema HS. Effectiveness of a risk-based visitor-prioritizing system at a sexually transmitted infection outpatient clinic. Sex Transm Dis 2007; 34:508–512.
11. Morre SA, Spaargaren J, Fennema JS, de Vries HJ, Coutinho RA, Pena AS. Real-time polymerase chain reaction to diagnose lymphogranuloma venereum. Emerg Infect Dis 2005; 11:1311–1312.
12. Health Service Amsterdam STI outpatient clinic. Year report 2005. Health Service Amsterdam; 5 A.D. Dec 31.
13. de Vries HJ, Van der Bij AK, Fennema HS, Morre SA. Lymphogranuloma in men who have sex with men; a prospective case controlled study. 2006 Jun 18; San Francisco, CA: International Chlamydia Symposium, 2006: 105–108.
14. de Vries HJ, Fennema JS, Morre SA. Lymphogranuloma venereum among men having sex with men; what have we learned so far? Sex Transm Infect 2006; 8:344.
15. Stoll M, Schmidt RE. Adverse events of desirable gain in immunocompetence: The Immune Restoration Inflammatory Syndromes. Autoimmun Rev 2004; 3:243–249.
16. Morre SA, Spaargaren J, Fennema JS, de Vries HJ. Molecular diagnosis of lymphogranuloma venereum: PCR-based restriction fragment length polymorphism and real-time PCR. J Clin Microbiol 2005; 43:5412–5413.
17. Gotz HM, van DG, Niesters HG, den Hollander JG, Thio HB, de ZO. A cluster of acute hepatitis C virus infection among men who have sex with men–results from contact tracing and public health implications. AIDS 2005; 19:969–974.
18. Savage D. Savage Love; How to use “Santorum” in a Sentence. New York City, The Village Voice (July 2–8) 2003.
19. Schreeder MT, Thompson SE, Hadler SC, et al. Hepatitis B in homosexual men: Prevalence of infection and factors related to transmission. J Infect Dis 1982; 146:7–15.
20. Ndimbie OK, Kingsley LA, Nedjar S, Rinaldo CR. Hepatitis C virus infection in a male homosexual cohort: Risk factor analysis. Genitourin Med 1996; 72:213–216.
21. Koedijk F, de Boer I, de Vries H, Thiesbrummel H, van der Sande M. An ongoing outbreak of lymphogranuloma venereum in the Netherlands, 2006–2007. Euro Surveill 2007; 12:E070419.2. Available from: http://www.eurosurveillance.org/ew/2007/070419.asp#2